EMA Approves Ocular Formulation of Bevacizumab EMA Approves Ocular Formulation of Bevacizumab
Europe has approved the use of monoclonal antibody bevacizumab for the treatment of neovascular age-related macular degeneration.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 22, 2024 Category: Drugs & Pharmacology Tags: Ophthalmology Source Type: news

Inflammation-reducing drug shows no benefit for dry age-related macular degeneration in NIH trial
Dry AMD affects part of the eye ’s retina that allows for clear central vision. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - March 20, 2024 Category: American Health Source Type: news

Roche launches top selling eye drug Vabysmo in India
Roche Pharma India launches Vabysmo, a medication for neovascular age-related macular degeneration and diabetic macular edema in India. The drug is cost-effective and collaborates with government and insurance companies for patient access. Vabysmo achieves global sales and offers durable treatment for retinal vision loss. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 5, 2024 Category: Pharmaceuticals Source Type: news

Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada
Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalmology product for neovascular and age-related macular degeneration, in Canada by July 1, 2025. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 4, 2024 Category: Pharmaceuticals Source Type: news

Diagnosed With Macular Degeneration? Here's What You Need to Know
TUESDAY, Feb. 6, 2024 -- Age-related macular degeneration can lead to vision loss in seniors, but new therapies have offered fresh hope for preserving eyesight later in life, eye experts say.These cutting-edge therapies benefit both the dry and wet... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 6, 2024 Category: General Medicine Source Type: news

Cheating death: How cancer cells escape
Cell death is fundamental to life and, thus, healthy aging. In the realm of cellular biology, ferroptosis (a form of programmed cell death) has emerged not only as a focal point of research for its potential in eliminating cancer cells, but also its role in a plethora of other diseases, including neurodegenerative diseases such as Alzheimer's disease, eye diseases such as Retinitis pigmentosa and age-related macular degeneration, as well as ischemia, cardiovascular disease, liver disease, acute kidney injury and inflammation. (Source: World Pharma News)
Source: World Pharma News - February 2, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New long-term data for Roche ’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry visionUp to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apartDetailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DMEBasel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) i...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news

New long-term data for Roche ’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry visionUp to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apartDetailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DMEBasel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) i...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news

February Declared as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month by Prevent Blindness
Prevent Blindness Provides Free Resources on AMD and Low Vision, Including Fact Sheets, Social Media Graphics, Expert and Patient Videos, An Interactive Patient Guide, and More CHICAGO, Jan. 29, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 29, 2024 Category: Pharmaceuticals Tags: PDT Source Type: news

Metformin Shows Potential to Prevent Neovascular AMD Metformin Shows Potential to Prevent Neovascular AMD
A case-control study of 174,000 individuals found that use of metformin was associated with a reduced odds of developing wet, age-related macular degeneration.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 23, 2024 Category: Consumer Health News Tags: Ophthalmology Source Type: news

Peninsula drugmaker divests biosimilar eye drug for $170M cash
The drug, a lookalike version of Genentech's Lucentis for wet age-related macular degeneration and other eye conditions, was licensed in 2019 by Coherus. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 22, 2024 Category: Biotechnology Authors: Ron Leuty Source Type: news

Outdoor Artificial Light at Night Tied to New Exudative AMD
THURSDAY, Jan. 18, 2024 -- Higher levels of residential outdoor artificial light at night (OALAN) are associated with an increased risk for incident exudative age-related macular degeneration (EAMD), according to a study published online Jan. 16... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2024 Category: Pharmaceuticals Source Type: news

Does More Outdoor Light at Night Help Cause Macular Degeneration?
TUESDAY, Jan. 16, 2024 -- As levels of nighttime artificial outdoor light rise, so do the odds for a leading cause of vision loss, age-related macular degeneration (AMD). South Korean researchers found that people living in areas of that country... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 16, 2024 Category: General Medicine Source Type: news